SUPPLEMENTARY INFORMATION: On Wednesday, November 8, 1995, there was published in the Federal Register, 60 FR 56338, a proposed consent agreement with analysis In the Matter of The Stop & Shop Companies, Inc., et al., for the purpose of soliciting public comment. Interested parties were given sixty (60) days in which to submit comments, suggestions or objections regarding the proposed form of the order.

No comments having been received, the Commission has ordered the issuance of the complaint in the form contemplated by the agreement, made its jurisdictional findings and entered an order to divest, as set forth in the proposed consent agreement, in disposition of this proceeding.

(Sec. 6, 38 Stat. 721; 15 U.S.C. 46. Interprets or applies sec. 5, 38 Stat. 719, as amended; 15 U.S.C. 45)

Donald S. Clark,

Secretary.

[FR Doc. 96–12706 Filed 5–20–96; 8:45 am]

BILLING CODE 6750–01–M

[Dkt. C–3244]

West Point-Pepperell, Inc.; Prohibited Trade Practices and Affirmative Corrective Actions

AGENCY: Federal Trade Commission.

ACTION: Set aside order.

SUMMARY: This order reopens a 1988 consent order—which required West Point to divest certain towel and sheet manufacturing facilities and prohibited West Point, for 10 years, from making certain acquisitions in the sheet and towel industries without prior Commission approval—and sets aside the consent order pursuant to the Commission's Prior Approval Policy Statement, under which the Commission presumes that the public interest requires setting aside the prior approval requirements in outstanding merger orders and making them consistent with that policy.

DATES: Consent order issued December 14, 1988. Set aside order issued October 4, 1995.[1]

FOR FURTHER INFORMATION CONTACT: Daniel Ducore, FTC/S–2115, Washington, D.C. 20580, (202) 326–2526.

SUPPLEMENTARY INFORMATION: In the Matter of West Point-Pepperell, Inc. The prohibited trade practices and/or corrective actions are removed as indicated.

Authority: Sec. 6, 38 Stat. 721; 15 U.S.C. 46. Interpret or apply sec. 5, 38 Stat. 719, as amended; sec. 7, 38 Stat. 731, as amended; 15 U.S.C. 45, 18)

Donald S. Clark,

Secretary.

[FR Doc. 96–12707 Filed 5–20–96; 8:45 am]

BILLING CODE 6750–01–M

[1] Copies of the Consent Order and Set Aside Order are available from the Commission's Public Reference Branch, H–130, 6th Street and Pennsylvania Avenue NW., Washington, D.C. 20580.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Citizens Advisory Committee on Public Health Service Activities and Research at Department of Energy (DOE) Sites: Idaho National Engineering Laboratory Health Effects Subcommittee

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announce the following meeting.

Name: Citizens Advisory Committee on Public Health Service Activities and Research at Department of Energy (DOE) Sites: Idaho National Engineering Laboratory Health Effects Subcommittee (INEL).

Times and Dates: 8 a.m.–5 p.m., June 5, 1996; 7 p.m.–9 p.m., June 5, 1996; 8 a.m.–12:15 p.m., June 6, 1996.

Place: Quality Inn Pocatello Park Hotel, 1555, Pocatello Creek Road, Pocatello, Idaho 83201.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

Purpose: The Subcommittee is charged with providing advice and recommendations to the Director, CDC, and the Administrator, ATSDR, regarding community, American Indian Tribes, and labor concerns pertaining to CDC's and ATSDR's public health activities and research at respective DOE sites. Activities shall focus on providing a forum for community, American Indian Tribal, and labor interaction and serve as a vehicle for community concern to be expressed as advice and recommendations to CDC and ATSDR.

Matters To Be Discussed: Agenda items include: the Biological Effects of Radiation—Radionuclides releases other than plutonium that could cause health effects, declassification issues, high efficiency particulate air filters, environmental monitoring—past and present, discussion of Phase I, and other than radionuclides present at INEL (e.g., chemicals: most toxic and carcinogenic).

Agenda items are subject to change as priorities dictate.

Contact Persons For More Information: Arthur J. Robinson or Nadine Dickerson, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 4770 Buford Highway, NE, M/S F–35, Atlanta, Georgia 30341–3724, telephone 770/488–7040, FAX 770/488–7044.

Dated: May 15, 1996.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–12686 Filed 5–20–96; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 92N–0438]

Worldwide Biologicals, Inc.; Revocation of U.S. License No. 832–003

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the revocation of the establishment license (U.S. License No. 832–003) and the product license issued to Worldwide Biologicals, Inc., for the manufacture of Source Plasma. A notice of opportunity for a hearing on a proposal to revoke the licenses was published in the Federal Register of March 22, 1993. Worldwide Biologicals, Inc., subsequently requested a hearing. In a separate legal proceeding, the responsible head of Worldwide Biologicals, Inc., voluntarily surrendered U.S. License No. 832–003 pursuant to a plea agreement with the United States Attorney for the Southern District of Ohio and the Office of Consumer Litigation, United States Department of Justice, which represented FDA in the proceeding. In light of Worldwide Biologicals, Inc.'s, surrender of its license, the firm's request for an opportunity for a hearing on the issue of license revocation became moot. FDA, therefore, proceeded to revoke the licenses.

DATES: The revocation of the establishment license (U.S. License No. 832–003) and product license became effective September 29, 1994.

FOR FURTHER INFORMATION CONTACT: Stephen M. Ripley or Tracey H. Forfa, Center for Biologics Evaluation and Research (HFM–635), Food and Drug Administration, 1401 Rockville Pike,

Rockville, MD 20852–1448, 301–594–3074.

SUPPLEMENTARY INFORMATION: FDA has revoked the establishment license (U.S. License No. 832–003) and the product license for the manufacture of Source Plasma issued to Worldwide Biologicals, Inc., 508–A Owen Dr., Fayetteville, NC 28304.

By letter dated June 15, 1992, issued pursuant to 21 CFR 601.5(b), FDA notified the firm of FDA's intent to revoke U.S. License No. 832–003 and announced its intent to offer an opportunity for a hearing. In a facsimile dated June 24, 1992, the firm notified FDA of its intent to request a hearing on the proposed license revocation.

In the Federal Register of March 22, 1993 (58 FR 15351), FDA issued a notice of opportunity for a hearing, pursuant to 21 CFR 12.21(b), on the proposal to revoke the establishment license (U.S. License No. 832–003) and product license issued to Worldwide Biologicals, Inc., for the manufacture of Source Plasma. As described in the notice of opportunity for a hearing, the grounds for the proposed license revocation included the following: (1) The results of FDA inspections of the firm conducted from June 24 through July 2, 1991; January 17 through January 27, 1992; and May 5 and 6, 1992; as well as from the inspection of Worldwide Biologicals, Inc., 1085 Ohio Pike, Cincinnati, OH, the site of the testing laboratory approved to perform all required testing for the Fayetteville facility, from July 18 through August 26, 1991; (2) a determination by FDA that the deviations documented during the inspections of the firm demonstrated significant noncompliance with the applicable regulations and standards in the firm's license; and (3) a determination by FDA that there was no assurance that the firm would properly implement a corrective action plan that it had proposed. FDA's determination was based on the firm's failure to adequately implement previously promised corrections. Documentation in support of the proposed revocation had been placed on file for public examination with the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

Following publication of the notice of opportunity for a hearing on March 22, 1993, FDA's Dockets Management Branch received two letters, dated April 12, 1993, and May 20, 1993, from the firm's responsible head. In the letter of April 12, 1993, Worldwide Biologicals, Inc., requested a hearing on the proposed license revocation. In the letter of May 20, 1993, Worldwide Biologicals, Inc., submitted its request for a hearing and set forth information and factual analyses to support its request.

While the request for a hearing was pending, representatives of the U.S. Department of Justice, on behalf of FDA, charged the responsible head of Worldwide Biologicals, Inc., with criminal violations of Federal laws governing the manufacturing, labeling, and shipping of human blood plasma. On April 6, 1994, the responsible head entered into a plea agreement with the United States Attorney for the Southern District of Ohio and the Office of Consumer Litigation, United States Department of Justice. In a superseding plea agreement filed on April 29, 1994, with the clerk of the United States District Court, Southern District of Ohio, Western Division, the responsible head of the firm agreed to surrender U.S. License No. 832 immediately upon sentencing. Sentencing took place on September 23, 1994. FDA notified Worldwide Biologicals, Inc., by letter of September 29, 1994, that the licenses had been revoked.

Based on the voluntary surrender of U.S. License No. 832, Worldwide Biologicals Inc.'s request for a hearing on the issue of license revocation became moot. Although the revocation proceedings that FDA initiated only pertained to the firm's Fayetteville, NC location (U.S. License No. 832–003), the surrender of U.S. License No. 832 affects all Worldwide Biologicals, Inc., locations under that license.

Accordingly, under 21 CFR 601.5, section 351 of the Public Health Service Act (42 U.S.C. 262), and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Biologics Evaluation and Research (21 CFR 5.68), the establishment license (U.S. License No. 832–003) and the product license for the manufacture of Source Plasma issued to Worldwide Biologicals, Inc., were revoked, effective September 29, 1994.

This notice is issued and published under 21 CFR 601.8 and the redelegation at 21 CFR 5.67.

Dated: May 2, 1996.

Kathryn C. Zoon,

Director, Center for Biologics Evaluation and Research.

[FR Doc. 96–12688 Filed 5–20–96; 8:45 am]

BILLING CODE 4160–01–F

Grassroots Regulatory Partnership Meeting; Pacific Region San Francisco District Office; Medicated Feed Industry

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of a public meeting.

SUMMARY: The Food and Drug Administration (FDA) (Office of External Affairs, Office of Regulatory Affairs, Office of the Pacific Region, and the Center for Veterinary Medicine) is announcing a free public meeting as a followup to a meeting held in April 1995. FDA's San Francisco District Office (Pacific Region) and the Center for Veterinary Medicine will meet with interested persons in the Pacific Region to address specific issues related to the medicated feed industry to help the industry comply with FDA regulations. The agency is holding this meeting to promote the President's initiative for a partnership approach with front-line regulators and the people affected by the work of this agency.

DATES: The public meeting will be held on Friday, May 31, 1996, from 8 a.m. to 4:30 p.m.

ADDRESSES: The public meeting will be held at the Red Lion Inn, 1401 Arden Way, Sacramento, CA 95815. Attendees requiring overnight accommodations may contact the hotel at 916–922–8041.

FOR FURTHER INFORMATION CONTACT:

Regarding the Sacramento area: Karen L. Robles or Susan R. Nelson, Food and Drug Administration, 650 Capitol Mall, rm. 6002, Sacramento, CA 95814, 916–498–6403 or 916–498–6400 or FAX 916–498–6401.

Regarding the Fresno area: Robert J. Anderson, Food and Drug Administration, 2202 Monterey St., suite 104E, Fresno, CA 93721, 209–487–5321 or FAX 209–487–5305.

SUPPLEMENTARY INFORMATION: In the Federal Register of April 20, 1995 (60 FR 19753), FDA announced that a series of Grassroots Regulatory Partnerships meetings would be held. This document announces a free public meeting as a followup to the meetings held in April 1995. Those persons interested in attending this public meeting should FAX their comments and registration including name, firm/organization, address, telephone and FAX numbers to the appropriate contact person listed above, by Friday, May 24, 1996.

There is no registration fee for this meeting, but advance registration is required. Space is limited and all interested parties are encouraged to register early. The goals of this meeting are to listen to concerns and ideas, and to identify next steps for the agency.